SEATTLE, Wash. and VANCOUVER, British Columbia, July 11, 2018 – – Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced an update on the cytisine development program following a meeting conducted with the United States (U.S.) Food and Drug Administration…
/Read More
SEATTLE, Wash. and VANCOUVER, British Columbia, June 26, 2018 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company, today announced positive results from a series of drug metabolism, drug-drug interaction and transporter studies with cytisine, the Company’s product candidate being evaluated as an aid to smoking cessation. The study demonstrated that cytisine has…
/Read More
SEATTLE, Wash. And VANCOUVER, British Columbia, June 19, 2018 – Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced the closing of an underwritten public offering of units for gross proceeds of $13.8 million, which includes the full exercise of…
/Read More
SEATTLE, Wash. and VANCOUVER, British Columbia, June 15, 2018 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced the pricing of an underwritten public offering of units for gross proceeds of $12 million, prior to deducting underwriting discounts and…
/Read More
SEATTLE, Wash. and VANCOUVER, British Columbia, June 11, 2018 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced that cytisine data, generated in collaboration with the University of Bristol, was published in Chem. These data show that via the…
/Read More